In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price target of $9.00, which represents a potential upside of 43% from where the stock is currently trading.

Brokmeier wrote, “CERS is a blood safety company with differentiated technology that reduces the risk of transfusion-transmitted infections, while saving hospitals money. Growth and profitability have struggled in recent years, but we believe accelerating adoption for platelets in the U.S., a potential 2H:17 CE Mark for red blood cells in Europe, and a recent federal grant to further the development of its U.S. red blood cell program position the company for double-digit growth for the next decade as it penetrates a $7.0B addressable market.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Bryan Brokmeier has a yearly average return of 1.1% and a 44% success rate. Brokmeier is ranked #1649 out of 4013 analysts.

Out of the 7 analysts polled by TipRanks, 6 rate Cerus stock a Buy, while 1 rates the stock a Hold. With a return potential of 36%, the stock’s consensus target price stands at $8.58.


The BioPortfolio is the only sure way to make profits trading biotech stocks. Learn more HERE and set up your top notch portfolio in seconds.